Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 oct. 2025 08h00 HE | Source: Hinge Bio, Inc.

Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis

BURLINGAME, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative multi-specific medicines,...
30 sept. 2025 19h30 HE | Source: Hinge Bio, Inc.

Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases

BURLINGAME, Calif. and TOKYO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative medicines, announced...
04 sept. 2025 07h00 HE | Source: Hinge Bio, Inc.

Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports

Paul Brunetta, M.D., joins as Chief Medical Officer; Kristen Quigley joins as Chief Clinical Operations Officer; Alpana Naresh, Ph.D., joins as Vice President and Head, CMC Strategy and Manufacturing ...
15 janv. 2025 07h00 HE | Source: Hinge Bio, Inc.

Hinge Bio Raises $30 Million Series A’ Financing to Develop Next-Generation Therapies via its Proprietary GEM-DIMER Platform

BURLINGAME, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company, today announced the close of a Series A’ financing led by Point72. Joining Point72 are...
14 nov. 2024 07h00 HE | Source: Hinge Bio, Inc.

Hinge Bio Presents Preclinical Data from its GEM-DIMER™ Programs Targeting B Cell Depletion at the American College of Rheumatology (ACR) Convergence 2024

BURLINGAME, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company, today announced that Daniel Capon, Ph.D., Chief Scientific Officer, and Juha Punnonen,...
14 août 2024 08h00 HE | Source: Hinge Bio, Inc.

Hinge Bio, Inc. Chief Scientific Officer, Daniel Capon, Ph.D., to Present its GEM-DIMER™ Platform Technology at the University of Oxford, Kennedy Institute of Rheumatology’s Annual Translational Research Conference

BURLINGAME, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately held biotechnology company in the San Francisco Bay Area, today announced that Daniel Capon, Ph.D., Founder &...
18 janv. 2023 08h00 HE | Source: Hinge Bio, Inc.

Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development

Barry Selick, Ph.D., successful biopharmaceutical scientist, senior executive and entrepreneur, appointed Chief Executive Officer Carin Rollins, Hinge Bio co-founder, becomes Chief Operating...